Smither John W — SEC Form 4 filings
SEC reporting owner CIK 1559583. 11 Form 4 filings on record with FilingPulse; latest filed 2026-09-09.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-02-15 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 6,250 shares.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 13,600 shares, $75,410 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: sale of 1,600 shares @ $25.32 ($40,512) in NewAmsterdam Pharma Co N.V., filed 2026-09-09.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | Director | 3 | — | 1 leg · 1,600 sh · $40,512 | 4 |
| GENELUX Corp (GNLX) | Director | 6 | 1 leg · 6,250 sh | 1 leg · 12,000 sh · $34,898 | 8 |
| Arcutis Biotherapeutics, Inc. (ARQT) | Chief Financial Officer | 1 | — | — | 4 |
| MBX Biosciences, Inc. (MBX) | Chief Financial Officer | 1 | — | — | 2 |
Form 4 filings — Smither John W
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale (S): 1,600 @ $25.32 | EDGAR |
| 2026-08-04 | 4 | MBX Biosciences, Inc. (MBX) | Grant/award (A): 28,000 @ $0 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | GENELUX Corp (GNLX) | Sale (S): 12,000 @ $2.91 | EDGAR |
| 2026-06-18 | 4 | GENELUX Corp (GNLX) | Grant/award (A): 28,409 @ $0 · Grant/award (A): 31,566 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 3,400 · Grant/award (A): 15,300 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | GENELUX Corp (GNLX) | Grant/award (A): 22,283 @ $0 · Grant/award (A): 28,576 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 6,960 · Grant/award (A): 32,500 (derivative) @ $0 | EDGAR |
| 2024-12-31 | 4/A | GENELUX Corp (GNLX) | Grant/award (A): 50,469 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | GENELUX Corp (GNLX) | Grant/award (A): 39,541 @ $0 · Grant/award (A): 50,469 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | GENELUX Corp (GNLX) | Purchase (P): 6,250 · Purchase (P): 6,250 (derivative) | EDGAR |
| 2024-02-15 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 2,793 · Grant/award (A): 8,572 · Disposition to issuer (D): 8,379 (derivative) · Disposition to issuer (D): 25,718 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1559583 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →